JPS6348225A - Carcinostatic agent - Google Patents

Carcinostatic agent

Info

Publication number
JPS6348225A
JPS6348225A JP61192169A JP19216986A JPS6348225A JP S6348225 A JPS6348225 A JP S6348225A JP 61192169 A JP61192169 A JP 61192169A JP 19216986 A JP19216986 A JP 19216986A JP S6348225 A JPS6348225 A JP S6348225A
Authority
JP
Japan
Prior art keywords
bleomycin
ifn
alpha
carcinostatic agent
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP61192169A
Other languages
Japanese (ja)
Inventor
Noboru Yamada
昇 山田
Takashi Nakae
中江 孝
Yasuo Ueda
上田 泰生
Takuji Doi
土居 卓治
Yutaka Morise
森勢 裕
Hirobumi Arimura
有村 博文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Green Cross Corp Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan filed Critical Green Cross Corp Japan
Priority to JP61192169A priority Critical patent/JPS6348225A/en
Publication of JPS6348225A publication Critical patent/JPS6348225A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To obtain a carcinostatic agent for treating laryngeal carcinoma by using bleomycin in combination with IFN-alpha. CONSTITUTION:A carcinostatic agent for the treatment of laryngeal carcinoma with bleomycin is produced by using interferon-alpha for improving the activity of the bleomycin as a main component. The IFN-alpha is a glycoprotein having a molecular weight of 15,000-24,000 and containing 165-166 amino acid units. It can be produced either by the cultivation (of leukocyte, lymphoblast, etc.) or by a genetic engineering method provided that the IFN is originated from human being. Bleomycin is a tumoricidal antibiotic separated from the cultured solution of an actinomycete (Streptomyces verticillus B 80-72) and is used in a form of hydrochloride, sulfate or the like. The IFN-alpha and the bleomycin are administered in combination at an amount of preferably 10<4>-10<9>IU/kg/dose and 0.01-50mg/kg/dose, respectively, by intravenous injection, hypodermic injection, intramuscular injection or the like.

Description

【発明の詳細な説明】 (イ)産業上の利用分野 本発明は、喉頭癌治療においてブレオマイシンを用いる
際に、作用増強を目的として投与することを特徴とする
インターフェロン−α(以下、IFN−αと省略)を主
成分とする制癌剤に関する。
DETAILED DESCRIPTION OF THE INVENTION (a) Industrial application field The present invention provides interferon-α (hereinafter referred to as IFN-α), which is administered for the purpose of enhancing the action when bleomycin is used in the treatment of laryngeal cancer. It relates to an anticancer drug whose main ingredient is

(ロ)従来技術 IFN−αのヒト由来癌細胞に対する増殖抑制活性は既
にインビトロのみでな≦ごヌードマウスを世いたインビ
ボにおいても検討され、I FN−αが癌細胞の増殖を
抑制することが明らかにされている〔インターフェロン
(Interferon)、、  2 + 、13−4
6(1980) ;ジャーナル・オブ・インターフェロ
ン・リサーチ(J、Interferon Res、)
+ 2 (41,479−491(1982) )。
(b) Conventional technology The growth-suppressing activity of IFN-α against human-derived cancer cells has already been investigated not only in vitro, but also in vivo in nude mice, and it has been demonstrated that IFN-α suppresses the growth of cancer cells. It has been revealed [Interferon, 2+, 13-4
6 (1980); Journal of Interferon Research (J, Interferon Res)
+2 (41, 479-491 (1982)).

このIFN−αは既存の制癌剤とは異なった作用機序を
有するものと考えられている〔基礎と臨床、 19(,
11)、 339−346(1985) )。
This IFN-α is thought to have a different mechanism of action from existing anticancer drugs [Basic and Clinical Research, 19 (,
11), 339-346 (1985)).

一般に、制癌剤は副作用も顕著であり、そのために、体
薬期間を置いたり1.数種の制癌剤を少量ずつ併用する
措置などが取られている。
In general, anticancer drugs have significant side effects, and for this reason, it is necessary to take a period of physical therapy or 1. Measures are being taken to combine small doses of several anticancer drugs.

(ハ)本発明が解決しようとする問題点そこで、既存の
制癌剤と作用機序の異なるIFN−αを併用することに
より、各々の薬剤を単独で投与する場合に比べて高い抗
腫瘍効果の得られやことが示唆されている。
(c) Problems to be solved by the present invention Therefore, by combining existing anticancer drugs with IFN-α, which has a different mechanism of action, a higher antitumor effect can be obtained than when each drug is administered alone. It has been suggested that this is the case.

本発明者らは、このような示唆に基づき、IFN−αと
既存の制癌剤であるブレオマイシンの併用による癌治療
効果について検討した。そして、喉頭癌について併用効
果があることを見出して、本発明を完成した。
Based on this suggestion, the present inventors investigated the cancer therapeutic effect of the combination of IFN-α and bleomycin, an existing anticancer drug. Then, they discovered that the combination had an effect on laryngeal cancer, and completed the present invention.

従って、本発明の目的は、ブレオマイシンとIFN−α
を併用することにより、喉頭癌を治療する方法を提供す
ることにある。
Therefore, the object of the present invention is to combine bleomycin and IFN-α
The object of the present invention is to provide a method for treating laryngeal cancer by using the above-mentioned methods in combination.

(ニ)問題点を解決するための手段 本発明のIFN−αは、分子量15000〜24000
、アミノ酸165あるいは166個の糖蛋白である。そ
して、その由来は、ヒト由来のものであれば、培養(白
血球、リンパ芽球など)、あるいは遺伝子工学の手法に
より製造されたものであってもよい。
(d) Means for solving the problems The IFN-α of the present invention has a molecular weight of 15,000 to 24,000.
, a glycoprotein of 165 or 166 amino acids. As long as the origin is human, it may be cultured (leukocytes, lymphoblasts, etc.) or produced by genetic engineering techniques.

その結果としてはlXl0’〜1 xlO” IU/■
程度であればよい。
As a result, lXl0'~1 xlO'' IU/■
It is sufficient as long as it is of a certain extent.

IFN−αの製法としては、アンチマイクロボアル・エ
ージェント・アンド・ケモセラピイ(Antimicr
oboal^gent and Chemothera
py 20(1)+5、1981)などに記載の方法が
挙げられる。
The manufacturing method for IFN-α is antimicroboal agent and chemotherapy (Antimicr).
oboal^gent and Chemothera
py 20(1)+5, 1981).

また、ブレオマイシンは、放線菌(ストレプトマイセス
・バルチシウスB 80−72株)の培養液力ら分離さ
れた抗腫瘍性抗生物質であり、臨床的には、塩酸塩、硫
酸塩などが用いられている。(通常の使用量は5〜30
■/回程度である。)投与量としては、患者の年齢・病
態等に応じて、IFN−αは104〜109II/kg
/回、ブレオマイシンは0.01〜50■/ kg /
同程度とすることが好ましい。
Bleomycin is an antitumor antibiotic isolated from the culture solution of actinomycetes (Streptomyces balticius strain B 80-72), and its hydrochloride, sulfate, etc. are used clinically. There is. (Usually used amount is 5-30
■About 1/time. ) The dosage for IFN-α is 104 to 109 II/kg, depending on the patient's age and condition.
/time, bleomycin 0.01-50■/kg/
It is preferable that they be at the same level.

投与方法としては、各々の薬物の一回投与分を適当な溶
媒(生理食塩液、糖液など)1〜20m1程度に溶解し
た後、静注・皮下・筋注などで併用投与される。投与時
期は、同時でもよいが、適宜治療期間中においてずらし
て投与してもよい。
As for the administration method, a single dose of each drug is dissolved in about 1 to 20 ml of an appropriate solvent (physiological saline, sugar solution, etc.), and then the drugs are administered together by intravenous, subcutaneous, or intramuscular injection. The administration timing may be simultaneous, or may be administered at appropriate times during the treatment period.

本発明で有効な対象癌としては、喉頭癌が挙げられる。Target cancers that are effective in the present invention include laryngeal cancer.

特に、ヒト喉頭癌細胞株HEp −2(ATCC−CL
L23)に由来する喉頭癌に対して極めて有効である。
In particular, human laryngeal cancer cell line HEp-2 (ATCC-CL
It is extremely effective against laryngeal cancer derived from L23).

(ホ)本発明の効果 本発明によれば、ブレオマイシンとIFN−αを併用す
ることにより喉頭癌の治療に対して相乗効果を期待でき
る。
(e) Effects of the present invention According to the present invention, a synergistic effect can be expected in the treatment of laryngeal cancer by using bleomycin and IFN-α together.

従って、従来の制癌剤ブレオマイシンの投与量を減らす
ことが可能となり、副作用の軽減を図ることもできる。
Therefore, it is possible to reduce the dose of the conventional anticancer drug bleomycin, and it is also possible to reduce side effects.

(へ)実施例・実験例 本発明をさらに詳細に説明するために、実施例・実験例
を挙げるが、本発明はこれらによって限定されるもので
はない。
(f) Examples and Experimental Examples In order to explain the present invention in more detail, Examples and Experimental Examples will be given, but the present invention is not limited by these.

実験例1 ヒトvI&頭癌)(up−2を移植したヌードマウスを
用いて、IFN−αとブレオマイシンの併用効果につい
て検討した。
Experimental Example 1 The combined effect of IFN-α and bleomycin was investigated using nude mice transplanted with human vI & head cancer (up-2).

ヌードマウス(雄性、 Ba1b/c系+ nu/nu
+ 5週令)の背部皮下にヒト喉頭癌由来HEp−2株
(ATCC−CLL23)  5X106細胞数を移植
した。
Nude mouse (male, Ba1b/c line + nu/nu
5×10 6 cells of human laryngeal cancer-derived HEp-2 strain (ATCC-CLL23) were subcutaneously transplanted into the back of a mouse (+5 weeks old).

癌細胞移植後、腫瘍径が5’  10mm程度に増殖し
たマウスを一群4匹ずつに群分けした。
After cancer cell transplantation, the mice whose tumors had grown to about 5' 10 mm in diameter were divided into groups of 4 mice per group.

投与スケジュールは、IFN−αは、皮下へ週5回連続
投与で4週間、ブレオマイシンは腹腔内へ7目間隔で2
回投与とした(第1表)。
The administration schedule was as follows: IFN-α was administered subcutaneously 5 times a week for 4 weeks, and bleomycin was administered intraperitoneally 2 times every 7 days.
It was administered twice (Table 1).

Claims (2)

【特許請求の範囲】[Claims] (1)喉頭癌治療においてブレオマイシンを用いる際に
、作用増強を目的として投与することを特徴とするイン
ターフェロン−αを主成分とする制癌剤。
(1) An anticancer agent containing interferon-α as a main component, which is administered for the purpose of enhancing the action when bleomycin is used in the treatment of laryngeal cancer.
(2)喉頭癌がヒト喉頭癌細胞株HEp−2に由来する
特許請求の範囲第(1)項記載の制癌剤。
(2) The anticancer agent according to claim (1), wherein the laryngeal cancer is derived from the human laryngeal cancer cell line HEp-2.
JP61192169A 1986-08-19 1986-08-19 Carcinostatic agent Pending JPS6348225A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP61192169A JPS6348225A (en) 1986-08-19 1986-08-19 Carcinostatic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61192169A JPS6348225A (en) 1986-08-19 1986-08-19 Carcinostatic agent

Publications (1)

Publication Number Publication Date
JPS6348225A true JPS6348225A (en) 1988-02-29

Family

ID=16286831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61192169A Pending JPS6348225A (en) 1986-08-19 1986-08-19 Carcinostatic agent

Country Status (1)

Country Link
JP (1) JPS6348225A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027908A1 (en) * 1997-12-04 1999-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027908A1 (en) * 1997-12-04 1999-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines

Similar Documents

Publication Publication Date Title
JP4416839B2 (en) Treatment of secondary immune deficiency
JPH07505894A (en) Methods and compositions with fewer side effects for treating diseases with interferon
Mastino et al. Combination therapy with thymosin α1 potentiates the anti‐tumor activity of interleukin‐2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice
WO1991000103A1 (en) Method for protecting bone marrow against chemotherapeutic drugs and radiation therapy using transforming growth factor beta 1
JP3496937B2 (en) Medical composition containing consensus human interferon for treating cell proliferative disorders
KR102527457B1 (en) Phorbol Ester Compositions and Methods of Use for Treating or Reducing the Duration of Cytopenia
US20060281674A1 (en) S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
JPH11500119A (en) Inhibition of angiogenesis using interleukin 12
US5250296A (en) Immunostimulant agent containing interleukin-2 and 5&#39;-deoxy-5-fluorouridine
US6267968B1 (en) MDP derivatives and conjugates having haematipoietic function stimulating activity, and compositions containing same
US20050049191A1 (en) Method of administering a thymosin alpha 1 peptide
Strander Interferons and osteosarcoma
JPS6348225A (en) Carcinostatic agent
Priestman Interferons and cancer therapy
CN112569358B (en) Application of peinterferon and proto-oncogene product targeted inhibitor in synergistic inhibition of tumors
JP3064815B2 (en) Myeloma tumor anticancer agent
CN112569359A (en) Application of interferon and protooncogene product targeted inhibitor in synergistic treatment of kidney cancer
Bortolussi et al. Neonatal host defense mechanisms against Listeria monocytogenes infection: the role of lipopolysaccharides and interferons
JP3816522B2 (en) MDP derivatives and complexes exhibiting stimulating activity with respect to hematopoietic function, and compositions containing them
Hoelzer et al. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of myeloid leukemia
EP0405463A2 (en) Supporting agents for anti-cancer therapy
US6620411B1 (en) Method for inhibiting brain tumor or colon carcinoma
Cupissol et al. Spontaneous variations of IFN-g and RIL-2 sera concentrations, during 8 hours in advanced mal I gnant melanoma cancer patients
Besana et al. A single-centre experience with continuous intravenous infusion of recombinant interleukin-2±lak cells in metastatic renal cell cancer
Corti et al. Single-dose antibiotic prophylaxis with teicoplanin in cancer patients receiving continuous infusion interleukin-2 through central venous catheter